Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) Research & Development (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Research & Development for 17 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Research & Development fell 18.96% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 billion through Dec 2025, down 10.83% year-over-year, with the annual reading at $10.0 billion for FY2025, 10.83% down from the prior year.
  • Research & Development for Q4 2025 was $2.6 billion at Bristol Myers Squibb, up from $2.5 billion in the prior quarter.
  • The five-year high for Research & Development was $3.2 billion in Q4 2024, with the low at $2.2 billion in Q1 2021.
  • Average Research & Development over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2021.
  • The sharpest move saw Research & Development rose 28.77% in 2024, then decreased 18.96% in 2025.
  • Over 5 years, Research & Development stood at $2.5 billion in 2021, then fell by 0.32% to $2.5 billion in 2022, then fell by 1.27% to $2.5 billion in 2023, then grew by 28.77% to $3.2 billion in 2024, then fell by 18.96% to $2.6 billion in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.6 billion, $2.5 billion, and $2.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.